Value through Innovation07 February 2016

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
04.02.2016

SPIRIVA® RESPIMAT® Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents

-  
27.01.2016

Boehringer Ingelheim’s Giotrif® / Gilotrif® (afatinib) demonstrated superiority to Iressa® (gefitinib) in reducing the risk of disease progression and treatment failure in first-line treatment of patients with EGFR mutation-positive advanced non-small cell lung cancer

22.01.2016

European Commission confirms CMDh recommendation: Benefit/risk profiles of ambroxol and bromhexine products are favorable

15.01.2016

World Association for Buiatrics and Boehringer Ingelheim Animal Health announce “Ruminant Well-being Award”

13.01.2016

Boehringer Ingelheim and Arena Pharmaceuticals Collaborate to Advance Research in Schizophrenia

22.12.2015

Boehringer Ingelheim Invests in Europe: Pharma Company Expands Biopharmaceutical Production at Vienna Site

21.12.2015

Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation in lung cancer

18.12.2015

Boehringer Ingelheim presents strong lung cancer portfolio and long-awaited head-to-head data of afatinib compared to gefitinib at ESMO Asia 2015 Congress

15.12.2015

Sanofi and Boehringer Ingelheim Enter Exclusive Negotiations on Business Swap

14.12.2015

Initiation of first multinational study to evaluate safety of OFEV® (nintedanib) with add-on of pirfenidone in patients with IPF

08.12.2015

New Phase III study of nintedanib in people with systemic sclerosis and lung fibrosis

02.12.2015

Boehringer Ingelheim and MD Anderson Cancer Center join forces to discover new treatment approaches for pancreatic cancer

30.11.2015

Lung cancer experts call for improved EGFR mutation testing to allow all eligible NSCLC patients access to personalised treatment

26.11.2015

Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)

17.11.2015

Time is of the essence for millions living with ‘neglected’ lung disease

16.11.2015

Boehringer Ingelheim named one of the most innovative companies worldwide

13.11.2015

New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)

11.11.2015

Boehringer Ingelheim will invest 11 billion euros in Research and Development in the next five years to accelerate the discovery of next generation medical breakthroughs

back 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16